ArticleNPJ breast cancer2021

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.

Fabio Puglisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.